Back to Journals » Transplant Research and Risk Management » Volume 6

Prevention of organ rejection in renal and liver transplantation with extended release tacrolimus

Authors Reschen M, O'Callaghan C

Received 13 May 2014

Accepted for publication 24 June 2014

Published 2 September 2014 Volume 2014:6 Pages 55—72

DOI https://doi.org/10.2147/TRRM.S41381

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Michael E Reschen, Christopher A O’Callaghan

Henry Wellcome Building, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

Abstract: Tacrolimus is the key immunosuppressant used to prevent allograft rejection in kidney and liver transplant recipients. Despite the efficacy of tacrolimus and adjunctive immunosuppressants, a substantial number of patients experience episodes of acute rejection and late graft loss. Nonadherence is an etiological factor in both acute rejection and graft loss. In 2007, a prolonged release version of tacrolimus became available that allows once daily administration, thus halving the pill burden compared to the standard twice-daily tacrolimus. An increasing number of studies in de novo transplantation and in treatment conversion have evaluated the pharmacokinetic profile, efficacy, and safety of prolonged-release tacrolimus. We have reviewed the literature on the use of prolonged-release tacrolimus and hope that this will be of value in the design of protocols for transplant immunosuppression.

Keywords: immunosuppression, kidney, hepatic, allograft, adherence

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]